(0.07%) 5 473.16 points
(0.11%) 39 155 points
(0.38%) 17 785 points
(0.06%) $80.88
(-3.66%) $2.66
(-0.79%) $2 312.30
(0.16%) $28.92
(3.67%) $1 022.60
(0.28%) $0.936
(0.70%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need...
Stats | |
---|---|
今日成交量 | 53 481 |
平均成交量 | 123 075 |
市值 | 1.65B |
EPS | $1.370 ( Q1 | 2024-05-03 ) |
下一个收益日期 | ( $-0.0200 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
50.18 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0260 (0.10%) |
音量 相关性
Galapagos NV 相关性 - 货币/商品
Galapagos NV 财务报表
Annual | 2023 |
营收: | $239.72M |
毛利润: | $239.70M (99.99 %) |
EPS: | $3.21 |
FY | 2023 |
营收: | $239.72M |
毛利润: | $239.70M (99.99 %) |
EPS: | $3.21 |
FY | 2022 |
营收: | $505.28M |
毛利润: | $493.20M (97.61 %) |
EPS: | $-3.32 |
FY | 2021 |
营收: | $484.85M |
毛利润: | $483.22M (99.66 %) |
EPS: | $-1.580 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。